BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 22, 2006
View Archived Issues
XBD-173: clinical anxiolytic effects without benzodiazepine-related adverse events
Read More
Phase II evaluation required to establish chemopreventive profile of myoinositol
Read More
Sapphire license ghrelin mimetic from Novo Nordisk
Read More
Shigamabs shown safe and well tolerated in phase I for E. coli infections
Read More
Progenics and Wyeth begin pivotal trials with POI drug candidate
Read More
AEterna Zentaris reports new company focus
Read More
Somanta and University of Bradford's ICT sign cancer research alliance
Read More
StemCells' neural stem cell product enters phase I for Batten disease
Read More
ChemGenex begins advanced clinical trials of Ceflatonin for CML
Read More
Avidia advances novel IL-6 inhibitor to phase I for Crohn's disease
Read More
Access advances towards commercialization of MuGard for oral mucositis
Read More
BioDelivery Science expects BEMA-fentanyl NDA filing in Q2 2007
Read More
Hospira to acquire Mayne
Read More
Endpoints not met in phase II trial with Nucryst's topical cream
Read More
Novel agents for treating seizures disclosed in recent Lundbeck patent
Read More
Recent Millenia Hope patent reports novel HIV-1 RNase H inhibitors
Read More
Novel treatment option for lipoprotein disorders jointly reported by Negma-Lerads and CNRS
Read More
Noxafil recommended for approval in Europe
Read More
Exenatide gains positive European opinion for the treatment of type 2 diabetes
Read More
Merck announces acquisition of Serono
Read More
Bionomics reports on novel inhibitors of Kv1.3 for the treatment of multiple sclerosis
Read More
Adjunctive estrogen therapy in women with schizophrenia enters phase II study: News in Context
Read More
Neurogen and Merck's novel TRPV1 antagonist presented at the ACS meeting
Read More
GSK reports on new MCHR1 antagonists for the treatment of obesity
Read More
Potent efficacy in vivo of Merck's novel glucagon receptor antagonists
Read More
